The vascular endothelium synthesizes nitric oxide (NO) from the terminal guanidino nitrogen atom( s) of L-arginine. NO accounts for the biological actions of endotheliumderived relaxing factor (EDRF). It is becoming apparent that the synthesis of NO from L-arginine not only explains endothelium-dependent vascular relaxation, but is a widespread mechanism for the regulation of cell function and communication. The evidence for this so far derives from work on vascular endothelial cells, macrophages, the central nervous system and neutrophils, although it is likely that this mechanism is also present in other tissues. This review will outline the evidence for this hypothesis and will consider its physiological and pathological implications.
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I n trodiiction
The vascular endothelium synthesizes nitric oxide (NO) from the terminal guanidino nitrogen atom( s) of L-arginine. NO accounts for the biological actions of endotheliumderived relaxing factor (EDRF). It is becoming apparent that the synthesis of NO from L-arginine not only explains endothelium-dependent vascular relaxation, but is a widespread mechanism for the regulation of cell function and communication. The evidence for this so far derives from work on vascular endothelial cells, macrophages, the central nervous system and neutrophils, although it is likely that this mechanism is also present in other tissues. This review will outline the evidence for this hypothesis and will consider its physiological and pathological implications.
The vascular endothelium
EDRF is a labile humoral substance released from the vascular endothelium which relaxes vascular smooth muscle and inhibits platelet aggregation and adhesion via stimulation of the soluble guanylate cyclase (for reviews see 11, 21). It has now been identified as NO 13-51, Furthermore, vascular endothelial cells in culture synthesize NO from the terminal guanidino nitrogen atom(s) of L-arginine [6, 71 . This reaction, which forms L-citrulline as a co-product and is NADPHdependent 181, is specific, since other analogues of L-arginine, including its D-enantiomer, are not substrates. In addition, one analogue, N"-monomethyl L-arginine ( L-NMMA ), inhibits the synthesis in a dose-dependent and enantiomerically specific manner 191.
In rabbit aortic rings [ 101 and guinea-pig pulmonary artery rings 1111, L-NMMA induces a small but significant endothelium-dependent contraction and inhibits the relaxation and the release of NO induced by acetylcholine (ACh). In the coronary circulation of the rabbit isolated heart, L-NMMA increases coronary perfusion pressure and inhibits AChinduced release of NO and fall in coronary perfusion pressure [ 121. More significantly, in the anaesthetized rabbit, L-NMMA induces a dose-dependent, long-lasting increase in mean arterial blood pressure and inhibits the hypotensive action of ACh without affecting that of the endotheliumindependent vasodilator, glyceryltrinitrate [ 131. All these actions of L-NMMA can be reversed by L-arginine in a way which suggests a competition between the inhibitor and the substrate [8] .
These results indicate that there is, in the vasculature, a continuous utilization of L-arginine for the generation of NO and that this NO plays a role in the control of vascular tone and blood pressure. Whether NO is also involved in the modulation of smooth muscle cell replication or in the control of enzymes regulating cholesterol metabolism requires investigation.
Abbreviations used: EDRF, endothelium-derived relaxing factor; L-NMMA, N"-monomethyl t.-arginine; ACh, acetylcholine; LPS. lipopolysaccharide; NMDA, N-methyl-u-aspartate; NO [22] . This L-arginine-dependent pathway, which is distinct from arginase, has been shown to contribute to the microbiocidal and tumoricidal activities of macrophages, which include inhibition of mitochondria1 respiration, aconitase activity and DNA synthesis. These activities as well as the generation of NOT and NO,, are inhibited by L-NMMA The functions of the generation of NO by macrophages, other than as a cytotoxic mechanism, are not known. It is possible, however, that NO may regulate cyclic GMP levels in cells with which the macrophage comes in contact. Furthermore, generation of NO may alter the intracellular environment of the macrophage by the induction of specific changes in metabolism which facilitate its microbiostatic activity [24] . Whether this is subsequent to the elevation of cyclic GMP or is an independent mechanism requires investigation.
Since NO is released by inflammatory cells and vascular tissue and exerts powerful biological actions it is likely that it also plays a role as a mediator of inflammation.
The central nervous system
In 1977, the soluble fraction of brain synaptosomes was shown to contain a low-molecular-mass activating factor of the soluble guanylate cyclase [25] . This factor, whose action was prevented by haemoglobin, was subsequently identified as L-arginine (261. We have recently shown that in a rat brain synaptosomal preparation L-arginine is converted t o Lcitrulline with a concomitant increase in cyclic GMP 1271. Both of these processes are inhibited by L-NMMA. indicating that the enzyme system involved is similar to that in the endothelial cell and in the macrophage [8,9, 231. Recently, N-methyb-aspartate (NMDA), an excitatory amino acid known to elevate cyclic GMP levels in the brain, has been shown to induce the release of an EDRF-like material from rat cerebellar cells. The release of this factor, which is Ca? +-dependent, accounts for the elevation in cyclic GMP levels that follows NMDA receptor activation 1281.
The soluble guanylate cyclase is not uniformly distributed throughout the brain and its role is yet to be understood. Cholinergic and adrenergic stimulation, excitatory amino acids, some other amines, depolarizing agents, peptides, nitroso compounds and NO have all been shown to elevate cyclic GMP in the central nervous system (for review see 1291). It is possible that in many of these cases receptormediated activation of the formation of NO from L-arginine leads to stimulation of the soluble guanylate cyclase, resulting in a variety of biological consequences.
The L-arginine: NO-forming erizyme system
Although the precise details of the mechanisms involved remain to be elucidated, the existing evidence warrants the conclusion that L-arginine is converted into NO with the concomitant formation of L-citrulline.
The tissues from which most information is at present derived are the vascular endothelium, the macrophagc and 122-241. the central nervous system. In all three, the enzymejs) involved is soluble, NADPH-dependent, requires a divalent cation, and is inhibited by L-NMMA ( 8 , 2 3 , 271.
Circumstantial evidence already points to the formation of N O from L-arginine in other tissues (see Table I ). N O formation has recently been demonstrated in neutrophils [301 and we have found that this formation is inhibited by L-NMMA [31] . T h e effect of L-NMMA is reversed by L-arginine (31 I. When analysed in terms of substrate specificity, products and cofactor requirements, the similarities between the systems from different sources is remarkable (see Table 1 ). At present it is not yet possible to tell whether they are the same enzyme or a system of isoenzymes. T h e latter possibility is more likely since the enzymes from the different cells show small variations in their substrate specificity and in their susceptibility to inhibition by L-arginine analogues.
The exact mechanism whereby the terminal guanidino nitrogen atom(s) of L-arginine is liberated and subsequently oxidized to N O is not known. In the macrophage, an Larginine deiminase that liberates ammonia, which is then oxidized to NO-and NO, has been postulated [34] . So far the term deiminase has been used for a reaction in which the imino nitrogen is removed, without a rigorous identification of the enzyme. However, deiminases have only been clearly identified in bacteria [ 3 5 ] and other mechanisms such as N oxidation, which has recently been proposed [ 221, may be involved. Furthermore, the NADPH-dependence of the enzymes suggests a redox mechanism. Additional work will be required to clarify this process.
T h e release of E D R F is known to be dependent on extracellular calcium [36] . T h e way in which this relates to the requirement for divalent cations by the enzyme( s) involved in the generation of N O from L-arginine also requires elucidation.
Conclusions
Present evidence allows us to postulate that the formation of N O from L-arginine is a widespread transduction mechanism for activation of the soluble guanylatc cyclase, leading to a variety of functions in different cells. Cofactor It has been proposed that N O activates the soluble guanylate cyclase by interaction with the iron atom in the hacm of the enzyme. Furthermore, N O also binds to and oxidizes the Fez+ in haemoglobin. Whether all the biological actions of N O are mediated through an interaction with transition metals, or whether its nitrosating ability also contributes t o its actions, has yet to be established.
Administration of r-arginine induces the release of a number of hormones from the pancreas, the pituitary and the adrenal glands. It increases skin allograft rejection, increases tumour regression and decreases tumour recurrence and it also decreases cholesterol levels and atherogenesis in animals and man (for review see [371) . It is likely that at least some of these actions o f L-arginine arc mediated via the formation of NO. The use of L-NMMA. a specific inhibitor of the L-arginine: N O pathway in t i t m and in t i \ v . will help t o identify which of the actions of L-arginine are mediated via this pathway.
T h e precise distribution of this pathway in the body remains to be studied and for this a systematic investigation of the biological actions of L-arginine and the correlation between this and the distribution of the soluble guanylate cyclase in tissues will be necessary.
Ititrodiictioti
Viruses arc intracellular parasites which must gain entry into the host cell before they can replicate and cause disease. The first step in the process of virus infection is the binding of the virus particle to receptor molecules on the cell membrane. followed by fusion of the outer coat of the virus with membranes cither at the cell surface o r in endosomes (Marsh, 1984). The receptor molecules do not, of course, exist simply t o let viruses in; rather the virus purloins a surface molecule as its receptor which has some other natural function.
It is now well known that CD4 ( T 4 ) antigen acts as the cell surface receptor on T-lymphocytes for the acquired immune 
Mechanism of I l I V e t i t~
HIV is an enveloped retrovirus bearing membrane glycoproteins, gp41 and gp120. that interact with host cell membranes (Haseltine. 1988 
Muppirigjitictioriul epitopes oti riral atid celliilar atitigetis
The HIV etiv gene encodes a glycoprotein precursor (gpl60) that is cleaved to form the outer virion envelope (gp120) and the transmembrane (gp4 1 ) glycoproteins. The production of recombinant proteins has revealed that gp120 binds to CD4 antigen with high affinity (Kowalski et ul., 1087; Lasky et al., 1987) . Mutational analysis indicates that the 40 amino acids at the C-terminus of gpl20 are essential for CD4 binding, though two other domains are also important. Although gp 120 sequences are highly diverse from one HIV strain to another, the CD4-binding domains arc conserved between HIV-1, HIV-2 and related simian immunodeficiency viruses (SIV) (Sattentau et al., 1988 The epitopes on the cellular CD4 antigen that recognize gp120 have been mapped using mabs and site-specific mutagenesis. The external portion of the CD4 molecule
